Thetis Pharmaceuticals is an emerging pharmaceutical company with a portfolio of novel best-in-class prescription drugs for the treatment of diabetes, hypertriglyceridemia and dyslipidemia. We will begin clinical studies on our lead candidates in late 2013 and early 2014.

Thetis is different in four important ways:

  • We leverage existing APIs to chemically create unique NMEs with enhanced pharmacokinetics and efficacy.
  • Phase 1 PK data in our class of compounds are indicative of efficacy.
  • Our candidates have an efficient pathway to approval in time and capital.
  • The Thetis IP portfolio is internally generated and completely company owned, and has strong prospects for global protection.

Our leadership team consists of the following executives:

  • Dr. Frank C. Sciavolino, President and Chief Scientific Officer, was the driving force behind the discovery and development of Pfizer's Zithromax, and the in-licensing of Celebrex from Searle.
  • Dr. Alexander (Zan) Fleming, Senior Clinical and Regulatory Officer, was previously Supervisory Physician in the FDA's Division of Metabolic and Endocrine Drug Products, and was responsible for landmark approvals of the first statin (lovastatin), Glucophage (metformin HCl), and other diabetic and endocrine therapies during the 1990's.
  • Dr. Larry Mylari, Chief Technology Officer, is an expert in type-2 diabetes and its complication and has numerous scientific publications and issued U. S. patents.
  • Mr. Gary Mathias, Chief Financial Officer, previously a senior vice president with GE Capital, is a business executive specializing in health care.
Partnering/Licensing Inquiries:
Dr. Frank Sciavolino
Chief Scientific Officer
167 Old Post Rd., 2nd Floor
Southport, CT 06890
Direct: (860) 213-1235
Other Inquiries:
Gary Mathias
Chief Financial Officer
167 Old Post Rd., 2nd Floor
Southport, CT 06890
Direct: (203) 470-7772